Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940902 | 1.00 | KMT2A (0.37) | KMT2ACYP2C9CYP2C19ANPEPGRIN2D | |
| SCHEMBL9940942 | 1.00 | KMT2A (0.37) | KMT2ACYP2C9CYP2C19ANPEPGRIN2D | |
| SCHEMBL30804405 | 1.00 | KMT2A (0.37) | KMT2ACYP2C9CYP2C19ANPEPGRIN2D | |
| SCHEMBL9343752 | 0.84 | SIGMAR1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL22127330 | 0.82 | IDO1 (0.41) | — | |
| SCHEMBL11043767 | 0.78 | CHRM2 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11046975 | 0.78 | CHRM2 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16985023 | 0.78 | ACHE (0.38) | KMT2A | |
| SCHEMBL11553791 | 0.74 | ANPEP (0.36) | KMT2ACYP2C9CYP2C19ANPEPSMN1; SMN2 | |
| SCHEMBL11545276 | 0.74 | ANPEP (0.36) | KMT2ACYP2C9CYP2C19ANPEPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-8946280-B2 | Plant growth regulating compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946280-B2 | Plant growth regulating compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946280-B2 | Plant growth regulating compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
| EP-2651890-B1 | STRIGOLACTAM DERIVATIVES AND THEIR USE AS PLANT GROWTH REGULATORS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20130303375-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20130303375-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20130303375-A1 | PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| WO-2013090696-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012080115-A1 | STRIGOLACTAM DERIVATIVES AND THEIR USE AS PLANT GROWTH REGULATORS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303375-A1 | PLANT GROWTH REGULATING COMPOUNDS | AREG, GHITM, FGF1 | KMT2A 4272/4885CYP2C9 4507/4885CYP2C19 4188/4885 |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | KMT2A 4731/4885CYP2C9 3844/4885CYP2C19 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.